
2021 has been a bumper year for cannabis and 2022 will be even bigger
While 2021 may have appeared to be a quiet year for cannabis stocks on the ASX but it’s been a busy year for the industry
Where FreshLeaf Analytics has been cited in the media
While 2021 may have appeared to be a quiet year for cannabis stocks on the ASX but it’s been a busy year for the industry
Ten years ago Collaroy resident Ashlee developed chronic neuropathic pain after a car accident left her with broken ribs.
Australia’s cannabis space has been moving forward, and progress continued in the first half of 2021. The country has seen the growth of domestic players,
FreshLeaf Analytics has released a comprehensive report on the current status of the Australian medicinal cannabis market. The FreshLeaf H1 2021 product, pricing and patient analysis report found
An industry report has warned Australia risks losing a billion dollar industry. Australia risks losing a billion dollar industry if medicinal cannabis is not correctly
You no longer need a prescription to get low-dose cannabidiol, though it’ll be months before approved products hit the shelves. And no, you can’t get
Cannabis oil firms chase approvals as over-the-counter sales are legalised Low dose cannabis oil can be bought over the counter at pharmacies from Monday for
Score check: Here’s how ASX pot stocks have responded to the US Senate result As ever, US politics is full of surprises — and ASX
From early 2021 you’ll technically be allowed to buy low-dose cannabis oil from pharmacies without a prescription. However, while the laws have been changed so
© 2022 All rights reserved, FreshLeaf Analytics
The H2 2021 report is FreshLeaf Analytics’ seventh market
report on patients, products and pricing in the Australian
medicinal cannabis market.